

# Hepatoprotective Activity of Polyherbal Extract

Sharukh A. Khan, Aref S. Shekh, Aslamkha C. Pathan

Anuradha College of Pharmacy, Chikhli, Buldhana, Maharashtra, India  
sharukh6785@gmail.com

**Abstract:** *The largest solid organ in the body, situated in the upper part of the abdomen on the right side. The liver has a multitude of important and complex functions, Including to manufacture proteins, Including albumin (to help maintain the volume Of blood) and blood clotting factors; to Synthesize, store, and process fats, Including fatty acids (used for energy) and cholesterol to Metabolize and store Carbohydrates (used as the source for the sugar in blood) to form and Secrete bile. That contains bile acids to aid in the intestinal absorption of fats and the fat- soluble Vitamins A, D, E, and K; to eliminate, by metabolizing or secreting, the potentially Harmful Biochemical products produced by the body, such as bilirubin, from the Breakdown of old red Blood cells and ammonia from the breakdown of proteins; And to detoxify, by metabolizing And/or secreting, drugs, alcohol, and Environmental toxins. Liver disease remains one of the serious health problems. Polyherbal extract was found to be much effective in protecting hepatocytes at selected dose. Recovery against paracetamol induced necrosis in their compact arrangement of hepatic cells was observed; whereas the section of liver of animals treated with Silymarin showed that extent of liver damage was lesser in magnitude as compared to the paracetamol treated animals.*

**Keywords:** Heoatotoxicity, Paracetamol, Silymarin, Polyherbal extract.

## I. INTRODUCTION

### Liver

The largest solid organ in the body, situated in the upper part of the abdomen on the right side. The liver has a multitude of important and complex functions, Including to manufacture proteins, Including albumin (to help maintain the volume Of blood) and blood clotting factors; to Synthesize, store, and process fats, Including fatty acids (used for energy) and cholesterol to Metabolize and store Carbohydrates (used as the source for the sugar in blood) to form and Secrete bile [1]. That contains bile acids to aid in the intestinal absorption of fats and the fat- soluble Vitamins A, D, E, and K; to eliminate, by metabolizing or secreting, the potentially Harmful Biochemical products produced by the body, such as bilirubin, from the Breakdown of old red Blood cells and ammonia from the breakdown of proteins; And to detoxify, by metabolizing And/or secreting, drugs, alcohol, and Environmental toxins. Liver disease remains one of the serious health problems [2].

### Current scinerio

Millions of people suffer and die from liver diseases every year. He incidence of different Kinds of liver disease like hepatitis, liver cirrhosis, liver cancer and other related diseases are Very common in Bangladesh. Most common liver diseases in Bangladesh are di ´ erent types of viral hepatitis. Virus related liver diseases are important causes of morbidity in Bangladesh. It has been reported that about 7percent to 10 percent (9.1 million to 13 million) of the Population have hepatitis B and at least 2 percent to 3 percent (2.6 million to 3.9million) have Hepatitis C infection [3]. Some have multiple viralinfections. Another study showed that about 3.5 Percent of pregnantmothers have hepatitis B infection.About 90 percent of mothers infected with Hepatitis B and are 'e'antigen (HBeAg) positive may transmit this virus to their children. He HBsAg is positive in 7.5 percent of healthy adult jobseekers So,it is easily understood that Only hepatitis B may produce a disastrous health situation in Bangladesh and throughout the World if is nottimely controlled. Hisa problem of grave concern and needs reliablescientific Based management [4]. Management options for common liver diseases such as cirrhosis, fatty liver And chronic hepatitis are problematic etcej. But medicinal herbs play a vital role in the management of variousliver disorders and there are Number of medicinal preparations inAyurveda recommended for the treatment of liver disorders. Medicinal plants are widely used all over the world including Bangladesh for production of both Traditional and modern drugs, and development of new drugs. Here are

more than 300 Traditional medicine manufacturers, including Unani, Ayurvedic and Homeopathy in Bangladesh. Maximum companies produce their patent drugs according to National Formulary. They claim that some of their drugs are effective in various hepatic disorders. Most of these Claims are based on old literature, folk sayings, occasional experiences, and traditional uses, but Not on any significant clinical or pharmacological studies and statistical data. So, the present Study was undertaken to investigate the effects of one polyherbal formulation named Rohitakarista on the status of hepatoprotection and release of marker enzymes in the serum. Dier Inducing hepatotoxicity by administering carbon tetrachloride (CCl<sub>4</sub>) in experimental rat [5].

#### **Blood supply of the liver**

The liver receives blood from two sources. From hepatic artery it receives Oxygenated blood and From the hepatic portal vein it receives deoxygenated blood Containing newly absorbed Nutrients, drugs and possibly microbes and toxins from Gastrointestinal tract. Branches of the Hepatic artery and the hepatic portal vein Carry blood into liver sinusoids, where oxygen, most Of nutrients and certain toxic Substance are taken up by the hepatocytes [6].

#### **Anatomy of liver**

The liver is a large, solid, gland situated in the right upper quadrant of the Abdominal cavity. Liver is reddish brown in Colour, soft in consistency and very Fraible. It weighs about 1600 gm In males and about 1300 gm in females. The liver Occupies the whole of the right Hypochondrium, the greater part of the epigastrium And extends into the left hypocondrium Reaching up to the left lateral line. The liver is the largest gland in the body. It secretes bile and performs various Other metabolic Functions. The liver is also called the 'heaper' from which we have The adjective hepatic [7].

#### **Function of liver**

##### **Carbohydrate metabolism**

The liver is especially important in maintaining a normal blood glucose level. When blood Glucose is low, the liver can break down glycogen to glucose and Realease glucose into the Bloodstream, when blood glucose is high it converts Glucose to glycogen and triglycerides for Storage liver can also convert certain Amino acid and lactic acid to glucose [8].

##### **Lipid metabolism**

Hepatocytes store some triglycerides, breakdown fatty acid to generate ATP, Synthesize Cholesterol and use cholesterol to make bile salt [9].

##### **Protein metabolism**

Hepatocytes deaminate amino acid so that the amino acid can be used for ATP Production or Converted to carbohydrates or fats, resulting toxic ammonia is Converted to less toxic urea, Which is excreted in urine. Hepatocyte synthesizes Most plasma proteins, such as alpha and beta Globulin, albumin, prothrombin and Fibrinogen [10].

##### **Processing of drugs and hormones**

The liver can detoxify substances such as alcohol or excreted drug such as Penicillin, Erythromycin and sulfonamides into bile [11].

##### **Storage**

In addition to glycogen, the liver is a prime storage site of certain vitamins (A, B<sub>12</sub>, D, E and K) And minerals (iron and copper), which are released from liver [12].

##### **Basic hepatic histopathology**

##### **Hepatocellular changes**

Hydropic change is a descriptive term applied to the hepatocytes with pale watery Cytoplasm And a normal nucleus. A wide variety of conditions produce this Relative lack of cytoplasmic Staining. Increased eosinophilia may occur with drug Related hydropic change of the smooth Endoplasmic reticulum. Active regeneration Of hepatocytes after neurosis as in several viral Hepatitis or recovery phase of fatty Liver, produce a widespread hepatocellular hydropic change As well as a Cobblestone pattern of liver cords. Hydropic change is also an indicator of Hepatocellular damage and is noted in acute viral hepatitis and drug induce hepatic Injury Including alcohol injury. Hepatocellular fat accumulations may be either large cytoplasmic bodies of foamy Fat. Fatty Liver occurs because of [13]

➤ Sudden increase in mobilization of fat from the periphery to the liver

- Relative lack of protein necessary for hepatocellular fat release
- Increased hepatocellular fat formation by metabolic changes and
- Decrease hepatocellular fat degradation.

### **Hepatocellular Necrosis**

Necrosis may be classified in many ways, including locations (zonal, periportal, Perivenular and Soon), mechanism (lytic, coagulative), amount (submassive versus Focal), cellular type (Lymphocytotoxic veruseshyline necrosis) and various Patterns are associated with different Etiologies factors. Zonal necrosis is a Common pattern of injury after an acute hepatic injury. Sharply demarcated Perivenular (Zone 3) coagulation necrosis is typical of several anoxic injury Or Acetaminophen injury and may be explained by differences in oxygenation and Activity of Drug metabolizing enzyme. Periportal necrosis (Zone 1) is not common And is noted in Eclampsia. Midzonal injury is reported for yellow fever [14]. Hepatocellular necrosis (hepatocytolysis) of the lytic type, with the associated Macriphage Activity that is so complete and rapid that dead hepatocytes are rarely Noted, such necrosis is common in viral. Hepatitis, alcoholic liver disease and many hepatotoxic reaction, and the type of Inflammatory Reaction varies in these conditions. Coagulative necrosis in the liver Is characterized by dying Hepatocyte that retain some staining of the cytoplasm and The nuclei basophilia and gradually Disappear. The Cells become shrunken and slowly disappear because of the action of Inflammatory cells. Acidophilic injury usually occurs in an isolated hepatocyte and is similar to Coagulative Necrosis except that the cytoplasm becomes more eosinophilic and Waxy and the nucleus may Be retained and be a dark. These bodies are common in Acute viral hepatitis, chronic active Hepatitis, severe burns and and other liver Disorders. Confluent necrosis is attributable to fusion Of focal or zonal necrosis And may result from intensive necrosis that bridge between different Zones. Submissive hepatic necrosis is recognized by Confluent necrosis that usually Involves Many perivenular areas and occurs most commonly in severe acute viral Hepatitis, drug injury Etc. Massive hepatic necrosis is distinguished from from Submissive hepatic necrosis by the Presence of a thin rim of viable appearing Around each portal tract [15].

### **Cirrhosis**

The currently accepted definition of cirrhosis may be applied to a liver with a Diffuse (that is Entire liver and not focal) and contain regenerative nodules, which Are masses of hepatocytes Lacking the normal blood flow because of the lack of Terminal hepatic venules. Regenerative or Hyperplastic nodules are required for the Identification of cirrhosis because altered blood flow And portal hypertension [16]. In Contrast hepatic fibrosis which is usually a precursor to cirrhosis, is Not associated. As frequently with portal hypertension. The development of hepatocellular Carcinoma is relatively common in cirrhosis with the required regenerative Nodules and is not as Frequent as it is in fibrosis. Cirrhosis is classified as micronodular cirrhosis applies to the liver in which nearly. All the Nodules are less than 3 mm diameter through some have used 1.5 mm as the Minimum diameter Because that is the diameter of a normal lobule. Examples Include alcohol cirrhosis, biliary tract Obstruction and hepatic venous obstruction. Macronodular cirrhosis applies if most of the Nodules are greater then 3 mm Diameter, and it occurs in two forms. The more common from Has nodules divided In thin Septa that are incomplete and have linking to portal tract [17]. This Pattern is Common in so called post hepatic cirrhosis to Macronodulartype is 2.25 years and Majority of patients have such progression. Alcoholic cirrhosis often contains fat Within the Hepatocytes and the parenchyma is increased in weight. Etiological Factors related to cirrhosis Include alcoholism, hepatitis B virus, various metabolic Diseases such as hemochromatosis, Wilson,s disease etc. Cirrhosis without Recognizable cause is called as "cryptogenic cirrhosis". The irreversibility of Cirrhosis has been emphasized in several experimental and clinical studies. If Cirrhosis is reversible, it must be very rare, through in the most convincing patient Having Biliary obstruction has been corrected surgically. Functionally more Important than nodular size In cirrhosis is the size of the entire hepatic mass, which Can be estimated with radioisotope Scans [18].

### **Enzyme that detect hepatocellular necrosis**

The liver contains thousands of enzymes, some of which are also present in serum In very low Concentrations. These enzymes have no known function in serum and Behave like other serum Proteins. They are distributed in plasma and intestinal Fluid and have characteristics half\_lives of Disappearance, usually measured in Days. The elevation of a

given enzyme activity in serum is Thought to primarily Reflect its increased rate of entrance into serum from damaged liver cells. Serum Enzyme tests can be grouped into two categories [19] :-

- 1) Enzymes whose elevation in serum reflects generalized damage to hepatocytes.
- 2) Enzymes whose elevation in serum primarily reflects cholestasis.

**Alanine aminotransferase (ALT)**

Liver cells produce the ALT level increase when liver cells are damaged or are Dying. The Higher the ALT levels, the more cell death or inflammation of the liver Is occurring. However ALTs are not always good indication of how well the liver Is functioning only a liver biopsy can Reveal that ALT level can remain low even. When the liver is inflamed or is developing scar Tissue, or during a child's immune Tolerant stage of disease [20].

**II. MATERIAL AND METHOD**

Drug and chemicals:

Sr. No	Drug and Chemicals	Company
1	Paracetamol	Research Lab
2	Country Made Liquor	Marketed formulation
3	Silymarin	SILYBON, Microlabs Ltd. Mumbai
4	Biochemical Estimation Kits (AST, ALT, ALP, TB and TP)	Pathozyme Kit
5	Ether(Anaesthetics)	Research Lab

Appratus and Equipment

Sr. No.	Equipment	Company	Specification
1	Analytical Weighing Balance	Shimadzu	Weighing capacity 0.1-200g
2	Cooling Centrifuge	Remi	-
3	Auto analyzer		

**Standard Drug:** Silymarin

**Priliminary Phytochemical**

**Investigation:**

The phytochemical estimation was performed

Sr. No.	Chemical Constituents	Test	Observation	Inference
1	Steroid	Salkowski Test	Chloroformed layer –red, acid layer–greenish	Steroid present
2	Saponin	Shinoda Test	Persistant Foam	Saponin present
3	Flavonoids	Saponins Foam Test	Slight pink colour	Flavonoid pres
4	Tannins & Phenolic compounds	Tannins Extract +FeCl3	Slight yellowcolour	Tannin present

**Animals:**

The Male wistar rats (150-180 g) were housed in the Animal House of Institute. Animal were maintained at standard environmental condition as per guidelines of CPCSEA with the free access of food and water before or during the experiment.

**Acute Oral Toxicity**

The testing of acute oral toxicity was performed by using OECD, Guidelines 423 (2001). The acute toxic class method set out in this Guideline is a stepwise procedure with the utilization of 3 animals of a single sex per step. Depending on

the mortality and/or the moribund status of the animals, on average 2-4 steps may be required to permit judgment on the acute toxicity of the test substance. This procedure is reproducible, uses very few animals and is able to rank substances in a similar manner to the other acute toxicity testing methods (Test Guidelines 420 and 425). For the said purpose, male, young and healthy wistar rats were selected. Weight of each animal was recorded. Animals were divided into different groups containing three animals each. Solutions of test extract were prepared in distilled water in different concentrations of 5, 50, 300 and 2000 mg/kg body weight. The different doses of test drug extract solution (5, 50, 300 and 2000 mg/kg bw) were given orally. Animals were observed individually at least once during the first 30 minutes after dosing, periodically during the first 24 hours (with special attention given during the first 4 hours), and daily then after, for a total of 14 days. After testing different doses of test drug extract solution (5, 50, 300 and 2000 mg/kg body weight), appropriate maximum tolerated safe dose was considered. 1/8th & 1/4th of the maximum tolerated safe dose was selected as treatment dose for further studies of pharmacological activities according to OECD, Guideline 423 [21].

### Experimental Procedure :

Experimental protocol approved by IAEC formed as per norms CPCSEA, Reg. No. (751/PO/abc/03/CPCSEA). In this study 36 albino wistar rat (150-180g) were used. These study based on the one screening animal model, and paracetamol induced hepatotoxicity (21days). Each screening model having six groups and each group having 6 animals.

### Paracetamol Induced Hepatotoxicity

For the paracetamol induced hepatotoxicity studies, paracetamol (500mg/kg po) suspension was prepared using 1% gum acacia and was administered to all animals except the animals of the normal control group. Silymarin (100 mg/kg po) was used as standard. Animals were divided into five groups of six animals each as stated [22].

Group design forhepatotoxicity

Sr.No.	Groups	Procedure(1to21days)
1	Control	Water(1ml/100g)
2	Negative contol	Paracetamol(1gm/kg body weight) for8days and water from 9to13days
3	Positive control	Paracetamol(1gm/kg body weight) +std.drug (silymarin100mg/kg p.o.)
4	Testdrug1	Paracetamol(1gm/kgbodyweight) +hydroalcoholic extract of <i>TestDrug</i> (100mg/kgp.o)
5	Testdrug2	Paracetamol(1gm/kgbodyweight) +hydroalcoholic extract of <i>TestDrug</i> (200mg/kgp.o)
6	Testdrug3	Paracetamol(1gm/kgbodyweight) +hydroalcoholic extract of <i>TestDrug</i> (400mg/kgp.o)

### Determination of Biochemical Parameters

The biochemical parameters like SGOT, SGPT, ALP and bilirubin were estimated using respective assay kits according to the methods described.

### Estimation of Serum Glutamic Pyruvic Transaminase (SGPT)

SGPT is a transaminase enzyme and is also called as Alanine transaminase (ALT) or Alanine Aminotransferase (ALAT). The enzyme is found in high concentration in the liver but is also present in a number of tissues, including the heart and skeletal muscles [Pratt et al., 2010].

The reversible transamination from alanine to  $\alpha$ -ketoglutarate is catalyzed by the enzyme and the products of this reaction are pyruvate and glutamate. A coenzyme namely pyridoxal phosphate is responsible for this transamination reaction which is transformed into pyridoxamine in the first stage of the reaction, when an amino acid is transaminated into a keto acid. The reduction of pyruvate and simultaneous oxidation of NADH to NAD are catalyzed by Lactate dehydrogenase SGPT is a transaminase enzyme and is also called as Alanine transaminase (ALT) or Alanine



Aminotransferase (ALAT). The enzyme is found in high concentration in the liver but is also present in a number of tissues, including the heart and skeletal muscles [Pratt et al., 2010]. The reversible transamination from alanine to  $\alpha$ -ketoglutarate is catalyzed by the enzyme and the products of this reaction are pyruvate and glutamate. A coenzyme namely pyridoxal phosphate is responsible for this transamination reaction which is transformed into pyridoxamine in the first stage of the reaction, when an amino acid is transaminated into a keto acid. The reduction of pyruvate and simultaneous oxidation of NADH to NAD are catalyzed by dehydrogenase [23].

**Procedure**

The method proposed by International Federation of Clinical Chemistry (IFCC) utilizing the LDH-NADH coupled assay, was used for ALT estimation. The reaction mixture (a mixture of 13mM  $\alpha$ -Ketoglutaric Acid, 400 mM D-Alanine, 0.2mM NADH, 1200 U/L LDH and Tris Buffer, pH 7.5) was reconstituted by adding distilled water to it. One ml of compound under investigation was taken out into suitable tube and warmed at 37°C for five minutes. About 0.10ml of sample was transferred to reagent to make total volume to 1.10 ml, mixed and incubated at 37°C for one minute. After one minute absorbance was recorded and readings were repeated for next two minutes after regular interval of one minute. Average difference in absorbance per minute ( $\Delta$ abs./min.) was calculated. Results were expressed as IU/L (amount of enzyme that catalyzes the transformation of one micromole of substrate per minute under specified conditions.) which was calculated by the formula [24].

$$\text{ALT (IU/L)} = \frac{\Delta\text{Abs./Min.} \times 1.10 \times 1000}{6.22 \times 0.10 \times 1.0} = \Delta\text{Abs./min.} \times 1768$$

Where,

- $\Delta$ Abs./Min. = Average absorbance change per minute
- 1.10 = Total reaction volume(ml)
- 1000 = Conversion of IU/ml to IU/L
- 6.22 = Millimolar absorptivity of NADH
- 0.10 = Sample Volume(ml)
- 1.0 = Light path in cm

**Estimation of Alkaline Phosphatase (ALP)**

Eradication of the phosphate groups from macromolecules like proteins, nucleotides and alkaloids is termed as dephosphorylation and is executed by a hydrolase enzyme Alkaline phosphatase (ALP, ALKP). The hydrolysis of phosphate esters is catalyzed by ALP which generates an organic radical and an inorganic phosphate in an alkaline atmosphere. The enzyme is found principally in bones and liver in the mammals and its hyperactivity may lead to the disease hyperalkaline phosphatasemia, which is characterized by marked increase in serum ALP levels and may lead to several other complications including primary biliary cirrhosis, hepatic lymphoma, malignant biliary obstruction, sarcoidosis and primary sclerosing cholangitis. An elevated level of alkaline phosphate is observed in hepatic and bone disorders which may be considered as preliminary counsel of severe health troubles [25].

**Procedure**

The method described by King (1965) was used to estimate the serum alkaline phosphatase. *p*- Nitrophenyl phosphate (pNPP) is employed in the modified technique which produces a yellow colored product upon hydrolysis by ALP. The maximum absorbance of the assay is achieved at 405 nm. The enzyme activity is said to be higher if reaction proceeds faster and vice versa. For each 96-well assay, 2 mL pNPP liquid substrate (10 mM), 5 mL Mg Acetate (5 mM) and 200 mL assay buffer. 200 mL distilled water (H<sub>2</sub>O) and 200 mL Tartrazine standard were mixed to form working solution and transferred into wells of a clear bottom 96-well plate. 5 mL samples were transferred into other wells and 195 mL working solution was also transferred to sample wells. This made a total volume of 200 mL into the sample wells. The

plate was tapped to mix the solutions. Optical density was read at 405 nm immediately after mixing and again after 4 mins on a plate reader. Kinetics of changes in OD was measured [26].

The activity of ALP IU/L of the sample was calculated as:

$$= \frac{(OD_{SAMPLE4} - OD_{SAMPLE0}) \times 1000 \times RV}{4 \times \epsilon \times l \times SV}$$

Where,

OD<sub>SAMPLE4</sub> = OD (405nm) values of sample at 4 min

OD<sub>SAMPLE 0</sub> = OD (405nm) values of sample at 0 min. 1000 = Conversion of IU/ml to IU/L

RV = Total reaction volume (200mL)

4 = Incubation time (min)

$\epsilon = 18.75 \text{mM}^{-1} \times \text{cm}^{-1}$

$l = (\text{lightpath, cm}) (OD_{Tart} - OD_{H_2O}) / (\epsilon \times c) = 1.321$

$\times \Delta ODSV = \text{Sample volume, i.e., 5mL}$

### Estimation of Total Bilirubin

Bilirubin is a reddish-yellow pigment found in bile. The production of the pigment usually takes place during the fate of heme. As the pigment liberated from the origin, it is in

—unconjugated or —indirect state. The insoluble unconjugated form of the compound binds to albumin and travels to the liver where it is transformed to —conjugated or —direct form by the treatment of. The conjugated form is water soluble and then moves into the bile. Maintenance and specific enzyme excretion of the pigment usually performed through the urine and stool and when the body cannot process the compound, unconjugated bilirubin can start to accumulate and a distinct yellow coloration of the eye and skin takes place. The person with hepatic disorders can develop dark yellow shade due to extreme hemolysis, biliary tract obstruction or buildup of the pigment in the body. [Annino, 1960]. Hyperbilirubinemia can also be coupled with pernicious anemia, hemolytic and hepatic jaundice, obstructive jaundice, and infectious hepatitis. Levels of this pigment can be evaluated with a blood test, and they may be checked as part of a workup [27].

### Procedure

The procedure illustrated by Malloy et al., (1937) was exercised for total bilirubin estimation. Total bilirubin, both conjugated and free, were estimated by the technique. The process describes the use of stabilized diazonium salt of 3,5-dichloroaniline and bilirubin resulting in the formation of azobilirubin which shows its maximum absorbance at 540 nm. The concentration of bilirubin present is directly comparative to the absorbance of the azobilirubin measured spectrophotometrically at 540 nm. 1.0 mL of total Bilirubin Reagent (3,5-dichlorophenyldiazoniumtetrafluoroborate, 0.36 mmol/L) was dispensed in test tube and 0.05 mL sample was added to it. The solutions were properly mixed before their incubation for 5 mins at room temperature. The absorbance was measured at 540nm. The results were articulated as mg/dL bilirubin with the help of the formula given [28].

$$\text{Total Bilirubin} = \frac{\text{Absorbance of Unknown}}{\text{Calibrator Value Absorbance of Calibrator}} \times$$

## III. RESULT

### PHYTOCHEMICAL SCREENING

Qualitative tests for various phytochemical constituents were executed on the leaf extracts and the results thus obtained were as mentioned in respective tables

TestName	Hydroalcoholic Extract
ForCarbohydrate Molish's test	-
ForReducingSugar Fehling's test	+
Benedict's test	-
ForMonosaccharide Barfoedtest	-
TestForSteroids Salkowskitest	+
Liebermann's burchard	+
Test For CardiacGlycosideBaljet's test	-
Legal's test	-
Keller's skillanitest	+
TestforsaponinsFoamtest	-
Heamolysistest	-
Test for AnthraquinoneGlycoside Borntrager's test	-
Modified Borntrager's Test	+
Test For FlavonoidsShinodatest	-
NaOHTest	+
Alkaloids TestDragendorff's test	+
Mayer's test	-
Hager's test	+
Wagner's test	+
Tanninsandphenoliccompound5%Fecl3 test	-
Dil.Iodinetest	-
Dil.HNO3 test	+
Brominewatertest	+
TerpenoidsSalkowski's test	-
Libermann-burchardTest	-

(+) Present; (-) Absent

### HEPATOPROTECTIVE ACTIVITY

The effect of paracetamol and the hydro alcoholic extracts of plants on various biochemical parameters like AST, ALT, ALP & serum bilirubin as well as on marker enzymes for hepatic functions like SOD, have been investigated. It was found that administration of paracetamol caused significant alteration in the level of biochemical parameters as well as of enzymes when compared to the normal. There was a significant ( $P < 0.001$ ) restoration of these enzyme levels on administration of the leaf extract in a dose dependent manner and also by silymarin at a dose of 100 mg/kg. hydro alcoholic extracts, 1/8th i.e. 250mg/kg & 1/4th i.e. 500 mg/kg of the dose was selected as treatment dose for further studies of pharmacological activities.

### ACUTE TOXICITY STUDIES

Different doses of hydro alcoholic extracts solution (5, 50, 300 and 2000 mg/kg bw) were given orally. Animals were observed individually at least once during the first 30 minutes after dosing, periodically during the first 24 hours (with special attention given during the first 4 hours), and daily then after, for a total of 14 days. Since no mortality was observed upto 2000 mg/kg of hydro alcoholic extracts, 1/8th i.e. 250mg/kg & 1/4th i.e. 500 mg/kg of the dose was selected as treatment dose for further studies of pharmacological activities.

### DETERMINATION OF BIOCHEMICAL PARAMETERS

The biochemical parameters like SGOT, SGPT, ALP and bilirubin were estimated using respective assay kits according to the methods described.




**ESTIMATION OF SERUM GLUTAMIC PYRUVIC TRANSAMINASE (SGPT)**

Effect of *Hydroalcoholic extract of test drug* and paracetamol on SGPT level of rats is shown in table. A single dose of paracetamol (500 mg/kg) caused significant elevation in the serum SGPT level when compared to normal group, while on treatment with *Hydroalcoholic extract of a significant dose dependent reduction* was observed in table.

Effect Hydroalcoholic extract of test drug on SGPT level.

Group	Treatment	Dose	No. of animals	SGPT(IU/L)
I	Normalcontrol	1 ml	6	34.74±2.283
II	Paracetamolcontrol	500mg/kg	6	99.85±0.7096 <sup>a</sup>
III	Silymarin	100mg/kg	6	48.53±0.9488 <sup>a</sup>
IV	Test-1200	200mg/kg	6	65.70±0.6678 <sup>a</sup>
V	Test-2400	400mg/kg	6	53.53±0.3355 <sup>a</sup>

ap<0.001; bp<0.01; cp<0.05; ns nonsignificant



Effect Hydroalcoholic extract of test drug on SGPT level


**ESTIMATION OF SERUM GLUTAMIC OXALOACETIC TRANSAMINASE (SGOT)**

Paracetamol (500 mg/kg) caused significant elevation in the serum SGOT level when compared to normal group, while on treatment with *Hydroalcoholic extract of test drug*, a significant dose dependent reduction was observed.

Effect of Hydroalcoholic extract of test drug on SGOT level

Group	Treatment	Dose	No. of animals	SGOT (IU/L)
I	Normalcontrol	1 ml	6	44.01±0.187
II	Paracetamolcontrol	500mg/kg	6	107.7±0.378 <sup>a</sup>
III	Silymarin	100mg/kg	6	53.43±1.06 <sup>a</sup>
IV	TestDrug200	200mg/kg	6	76.32±1.148 <sup>a</sup>
V	TestDrug400	400mg/kg	6	57.10±0.523 <sup>a</sup>

<sup>a</sup>p<0.001; <sup>b</sup>p<0.01; <sup>c</sup>p<0.05; <sup>ns</sup>non significant



Effect of Hydroalcoholic extract of test drug on SGOT level


### ESTIMATION OF ALKALINE PHOSPHATASE (ALP)

Effect of polyherbal extract and paracetamol on ALP level of rats is shown in table 4.38. A single dose of paracetamol (500 mg/kg) caused significant elevation in the serum ALP level when compared to normal group, while on treatment with hydroalcoholic extract of polyherbal extract, a significant dose dependent reduction was observed. A graph of comparative ALP level of different groups is shown in fig

Effect of polyherbal extract on ALP level

Group	Treatment	Dose	No.ofanimals	ALP(IU/L)
I	Normalcontrol	1 ml	6	41.70±1.952
II	Paracetamolcontrol	500mg/kg	6	114.8±0.735 <sup>a</sup>
III	Silymarin	100mg/kg	6	57.02±0.681 <sup>a</sup>
IV	Test-1200	200mg/kg	6	78.04±0.496 <sup>a</sup>
V	Test-2400	400mg/kg	6	62.57±0.602 <sup>a</sup>

*ap<0.001; bp<0.01; cp<0.05; ns non significant*



Effect of polyherbal extract on ALP level.

**ESTIMATION OF TOTAL BILIRUBIN**

Comparative effect of polyherbal extract and paracetamol on serum bilirubin level is presented in graph 4.30. There was a considerable increase in serum bilirubin level after paracetamol administration which was then reversed by polyherbal extract

Effect of *polyherbal* extract on bilirubin level

Group	Treatment	Dose	No. of animals	Total bilirubin (mg/dl)
I	Normal control	1 ml	6	1.232±0.081
II	Paracetamol control	500mg/kg	6	5.915±0.494 <sup>a</sup>
III	Silymarin	100mg/kg	6	2.307±0.148 <sup>b</sup>
IV	Test-1200	200mg/kg	6	4.007±0.379 <sup>a</sup>
V	Test-2400	400mg/kg	6	2.547±0.063 <sup>b</sup>

<sup>a</sup>*p*<0.001; <sup>b</sup>*p*<0.01; <sup>c</sup>*p*<0.05; <sup>ns</sup> non significant

**IV. CONCLUSION**

Polyherbal extract was found to be much effective in protecting hepatocytes at selected dose. Recovery against paracetamol induced necrosis in their compact arrangement of hepatic cells was observed; whereas the section of liver of animals treated with Silymarin showed that extent of liver damage was lesser in magnitude as compared to the paracetamol treated animals.

**REFERENCES**

- [1]. Guicciardi ME, Malhi H, Mott JL, Gores GJ. Apoptosis and necrosis in the liver. *Comprehensive Physiology*. 2013 Jan;3(2):977-1010.
- [2]. Fagan EA, De Swiet M. Disorders of the gastrointestinal tract. *Medical disorders in obstetric practice*. 1989:521-83.
- [3]. Alam S, Azam G, Mustafa G, Alam M, Ahmad N. Past, present, and future of hepatitis B and fatty liver in Bangladesh. *Gastroenterol Hepatol Open Access*. 2017;6(3):197.
- [4]. Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. *International journal of women's health*. 2014;6:605.
- [5]. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. *Molecules*. 2016 May;21(5):559.
- [6]. Ijaz S. The hepatic microcirculation of fatty liver. University of London, University College London (United Kingdom); 2006.
- [7]. Bismuth H. Surgical anatomy and anatomical surgery of the liver. *World journal of surgery*. 1982 Jan 1;6(1):3-9.
- [8]. Rajashekar V. Novel nutritional interventions in the manipulation of energy expenditure and blood glucose regulation in humans (Doctoral dissertation, University of Westminster).
- [9]. Karagianni P, Talianidis I. Transcription factor networks regulating hepatic fatty acid metabolism. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*. 2015 Jan 1;1851(1):2-8.
- [10]. Chew SF, Wilson JM, Ip YK, Randall DJ. Nitrogen excretion and defense against ammonia toxicity. *Fish physiology*. 2005 Jan 1;21:307-95.
- [11]. Zimmerman HJ. *Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver*. Lippincott Williams & Wilkins; 1999.

- [12]. Kuntz E. Biochemistry and functions of the liver. *Hepatology Principles and Practice: History• Morphology Biochemistry• Diagnostics Clinic• Therapy*. 2006:31-71.
- [13]. Myers MS, Rhodes LD, McCain BB. Pathologic anatomy and patterns of occurrence of hepatic neoplasms, putative preneoplastic lesions, and other idiopathic hepatic conditions in English sole (*Parophrys vetulus*) from Puget Sound, Washington. *Journal of the National Cancer Institute*. 1987 Feb 1;78(2):333-63.
- [14]. Myers MS, Rhodes LD, McCain BB. Pathologic anatomy and patterns of occurrence of hepatic neoplasms, putative preneoplastic lesions, and other idiopathic hepatic conditions in English sole (*Parophrys vetulus*) from Puget Sound, Washington. *Journal of the National Cancer Institute*. 1987 Feb 1;78(2):333-63.
- [15]. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor- induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. *The American journal of pathology*. 1995 May;146(5):1220.
- [16]. Wanless IR, International Working Party. Terminology of nodular hepatocellular lesions. *Hepatology*. 1995 Sep;22(3):983-93.
- [17]. Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, Francoz C, Denninger MH, Durand F, Bedossa P, Valla DC. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. *Journal of hepatology*. 2011 Mar 1;54(3):455-61.
- [18]. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Therapeutic advances in gastroenterology*. 2011 Nov;4(6):391-417.
- [19]. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nature protocols*. 2011 Jul;6(7):1060.
- [20]. Sussman NL, Chong MG, Koussayer T, He DE, Shang TA, Whisenand HH, Kelly JH. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. *Hepatology*. 1992 Jul;16(1):60-5.
- [21]. Arts JH, Muijser H, Jonker D, Van De Sandt JJ, Bos PM, Feron VJ. Inhalation toxicity studies: OECD guidelines in relation to REACH and scientific developments. *Experimental and Toxicologic Pathology*. 2008 Jun 27;60(2-3):125-33.
- [22]. Vermeulen NP, Bessems JG, Van de Straat R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. *Drug metabolism reviews*. 1992 Jan 1;24(3):367-407.
- [23]. Muhammed Shanavas VK. Evaluation of Anti-Oxidant and Hepatoprotective Activity of *Ixorea Coccinea* Leaf Extracts by Using Invitro and Invivo Models (Doctoral dissertation, Karpagam College of Pharmacy, Coimbatore).
- [24]. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. *Clinical chemistry*. 1978 Jan 1;24(1):58-73.
- [25]. Islam MT, Ali ES. Therapeutic interventions of diterpenes: Molecular mechanisms and promises. *World J. Pharm. Pharmaceut. Sci*. 2016 Aug 4;5(10):70-97.
- [26]. Panteghini M, Bais R. 19 Serum Enzymes. *Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics-E-Book*. 2014 Aug 14:318.
- [27]. Garland M. The practice laboratory—Part 2: biochemistry. *Veterinary Nursing Journal*. 2013 Mar 1;28(3):104-6.
- [28]. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. *Clinical chemistry*. 1978 Jan 1;24(1):58-73.